Related references
Note: Only part of the references are listed.Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2012)
Pharmacogenomics of the triazole antifungal agent voriconazole
Gerd Mikus et al.
PHARMACOGENOMICS (2011)
Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring
Arwa Hassan et al.
THERAPEUTIC DRUG MONITORING (2011)
Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients
Aniket Vadnerkar et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2010)
Periostitis Secondary to Prolonged Voriconazole Therapy in Lung Transplant Recipients
T. F. Wang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Voriconazole-Induced Phototoxicity Masquerading as Chronic Graft-versus-Host Disease of the Skin in Allogeneic Hematopoietic Cell Transplant Recipients
Asha R. Patel et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Hallucinations during voriconazole therapy
Dimitrios I. Zonios et al.
CLINICAL INFECTIOUS DISEASES (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
Norie Murayama et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections
Jan G. den Hollander et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Pharmacokinetic/pharmacodynamic profile of voriconazole
Ursula Theuretzbacher et al.
CLINICAL PHARMACOKINETICS (2006)
Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients
S Trifilio et al.
BONE MARROW TRANSPLANTATION (2005)
Discovery of new potentially defective alleles of human CYP2C9
J Blaisdell et al.
PHARMACOGENETICS (2004)
Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma
S Perea et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
